XM does not provide services to residents of the United States of America.

Financials lift Indian shares to record highs ahead of Fed policy decision



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA STOCKS-Financials lift Indian shares to record highs ahead of Fed policy decision</title></head><body>

Updates at 10:57 a.m. IST

By Bharath Rajeswaran

BENGALURU, Sept 18 (Reuters) -Indian shares rose marginally to record highs on Wednesday, led by financials which overpowered the drop in information technology stocks ahead of the U.S. Federal Reserve's rate decision.

Both the NSE Nifty 50 .NSEI and S&P BSE Sensex .BSESN rose about 0.2% each to record levels, as of 10:57 a.m. IST.

High-weightage financials .NIFTYFIN added 1.2%, outpacing the 3% drop in IT stocks .NIFTYIT. The pharma index .NIPHARM shed 0.5%. IT and pharma companies depend on the U.S. for a significant part of their revenue.

"Domestic markets are continuing their positive momentum, with the likelihood of the Fed rate cut bringing optimism," said Siddhartha Khemka, head of research of wealth management at Motilal Oswal Financial Services.

While the Fed is widely expected to lower rates, the size of the cut, whether 25 basis points or 50 bps, was still not clear. The odds of a 50-bps cut climbed to 65% from 34% last week.

While a bigger cut will likely see foreign funds shifting to emerging markets such as India in search of higher returns, it has prompted fears that the Fed may have begun its easing cycle a little too late, at the cost of economic growth.

The Fed's reason for its decision and commentary on future policy will likely influence the near-term trajectory of Indian equities in terms of foreign inflows and the outlook for the IT and pharma sectors.

Among individual stocks, Infosys INFY.NS slid 3% after Macquarie said the IT firm will continue to lag rival Tata Consultancy Services TCS.NS. TCS also dropped 2.7%.

Torrent Power TOPO.NS rose 2.5% on a letter of intent for a 1,500 megawatt pumped hydro storage project in the state of Maharashtra.

Emcure Pharma EMCU.NS rose 4% after Kotak Institutional Equities started coverage with "buy", citing likely sustained earnings growth.

India's currency and debt markets are closed for a holiday.



Reporting by Bharath Rajeswaran in Bengaluru; Editing by Savio D'Souza, Nivedita Bhattacharjee and Sumana Nandy

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.